Valneva (VLA) Q2 2026 earnings summary

Executive summary

• Product sales reached €64.0 million in H1 2026, down from €91.0 million in H1 2025, in line with expectations and reflecting planned third-party sales wind-down, distributor transitions, and lower outbreak-driven demand.

• Cash position improved to €121.5 million as of June 30, 2026, supported by disciplined management and proceeds from a recent €84 million reserved offering.

• Major restructuring program implemented, including workforce reduction, R&D reprioritization, and sale of the Nantes site, expected to positively impact P&L and cash flow in H2 2026 and beyond.

• Regulatory decisions for the Lyme disease vaccine candidate (LB6V) are anticipated within 12 months, with Pfizer optimistic about approval following strong Phase 3 results.

• Significant events include IXCHIQ withdrawal in the U.S., pilot vaccination campaign in Brazil, and appointment of Dr. Gerd Zettlmeissl as Chair of the Board.

Financial highlights

• Total revenues for H1 2026 were €65.8 million, down from €97.6 million in H1 2025, mainly due to the planned wind-down of third-party sales and phasing of product shipments.

• Net loss widened to €63.3 million from €20.8 million year-over-year, driven by lower sales, higher COGS, and one-off IXCHIQ-related charges.

• Adjusted EBITDA loss was €40.1 million, compared to €6.0 million in H1 2025.

• Operating loss increased to €49.9 million from €16.8 million, with about half attributable to IXCHIQ.

• Gross margin on total revenues was 9.6% (down from 51.7%), with gross profit falling to €6.3 million from €50.4 million.

Outlook and guidance

• Full-year 2026 product sales guidance reaffirmed at €135–150 million; total revenues expected at €145–160 million.

• Product gross margins are expected to improve in H2 2026 as one-off effects subside.

• Targeting financial self-sustainability in 2027, contingent on successful Lyme vaccine approval and commercialization.

• Continued investment in clinical and pre-clinical pipeline and stringent cost management.

• Regulatory decisions for the Lyme disease vaccine candidate anticipated within 12 months.